lumiracoxib.pdf (95.76 kB)
Download fileLumiracoxib (Novartis)
journal contribution
posted on 2023-05-26, 15:41 authored by Ding, C, Jones, GLumiracoxib, an inhibitor of cyclooxygenase 2 (COX-2), is under development by Novartis for the potential treatment of osteoarthritis, rheumatoid arthritis and pain. By late December 2000, phase III trials had been initiated and were ongoing in December 2001.
History
Publication title
IDrugsVolume
5Article number
12Number
12Pagination
1168-1172ISSN
1369-7056Publication status
- Published
Repository Status
- Open
